Please find attached for your attention, correspondence from
Alison Quinn, Health Protection Nurse, PHA.
The COVID-19 pandemic has highlighted
the importance of ensuring that all health and social care staff are protected
against disease. While there is currently no vaccine against COVID-19, there is
a vaccine against seasonal influenza, and it is important that all health and
social care workers have access to this vaccine. This year the flu vaccine will
be accessible by all health and social care workers, including all
members of the community pharmacy team.
The flu vaccination service is being
provided in over 350 participating pharmacies across NI, details can be found here.
Please note that an employee photo
identification badge/or other proof of employment in a health or social care
setting e.g. payslip, letter from employer on official letterhead or stamped
authorisation form (attached) plus photographic proof of identification will be
required.
Details of flu clinics organised by
occupational health in four of the five HSCTs are now available via here.
It is very important
that all health and social care staff are vaccinated against flu to protect
vulnerable patients and help to maintain services. Please encourage your staff
to take advantage of the opportunity to protect themselves and others against
flu by getting their flu vaccination.
This information should be brought to
the attention of all pharmacy staff and any locum staff who are connected with
your pharmacy.
Yours sincerely
SENT
FOR AND BEHALF OF GERARD GREENE | Chief Executive
Download
Dear
Colleague,
REMINDER: COMMUNITY PHARMACY ADVICE ON FACE COVERINGS
Please find below CPNI Contractor email sent on 19th August
2020 and also attached letter from the Chief Pharmaceutical Officer sent on 10th
September 2020 regarding face coverings.
Yours sincerely
SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive
The
following concessionary prices have been granted for October 2020:
Drug
Pack Size
Concessionary Price
Duloxetine
20mg gastro-resistant capsules
28
£7.99
Duloxetine
60mg gastro-resistant capsules
28
£4.10
Enalapril
10mg tablets
28
£5.49
Enalapril
20mg tablets
28
£10.00
Estradiol
1mg tablets
84
£6.89
Estradiol
2mg tablets
84
£6.89
Hydroxyzine
10mg tablets
84
£1.77
Moxonidine
200microgram tablets
28
£9.46
Moxonidine
300microgram tablets
28
£10.99
Moxonidine
400microgram tablets
28
£12.07
Naftidrofuryl
100mg capsules
84
£7.25
Olanzapine
15mg tablets
28
£3.95
Olanzapine
20mg tablets
28
£5.10
Oxytetracycline
250mg tablets
28
£9.10
Senna
7.5mg tablets
60
£2.76
Sertraline
100mg tablets
28
£6.72
Sertraline
50mg tablets
28
£4.74
Valsartan
160mg capsules
28
£12.01
This is the first update of concessionary prices
for October 2020.
Concessionary prices will be paid against the usual
code, no additional endorsements are needed.
Concessionary prices may be granted up until the
end of the month so CPNI will notify you of any further concessionary prices as
and when they are agreed.
Please continue to notify CPNI of any pricing
issues you are experiencing.
SENT FOR AND BEHALF OF KATHERINE KIDD | Head of Pharmacy Development
Dear Colleague
ADHERENCE SUPPORT: COMMUNITY PHARMACY REVIEW OF PATIENTS
RECEIVING MONITORED DOSAGE SYSTEMS (MDS)
Please find attached for your attention, correspondence from Joe
Brogan, Assistant Director of Integrated Care, Head of Pharmacy and Medicines
Management.
Given the challenges faced within the wider system, there is a
need to urgently address the current and ongoing need for pharmacy adherence
support particularly in order to plan for a potential second surge of COVID-19.
The letter outlines the process for a community pharmacy-led review and the
associated remuneration.
The purpose of the community pharmacy-led review is to identify
patients for whom MDS must continue as it is deemed vital in order for them to
manage their medicines safely. This review process should help to identify
patients where use of MDS may not be necessary or where other options may be
safely considered
A review of all eligible patients should be completed and the
summary template and claim form returned to your local HSCB office by Friday
16th October 2020.
Please bring the attached letter and associated documentation to
the attention of your pharmacist(s) involved in review of MDS patients.
If you have any queries in relation to this correspondence,
please contact your local HSCB Pharmacy Adviser in the first instance or the
CPNI office.
Yours sincerely
SENT
FOR AND BEHALF OF GERARD GREENE | Chief Executive
Download
Dear Colleague,
Please find attached a ‘Save the Date’ Document ahead of the
next Echo session, scheduled to take place on 27th October
2020 from 7.30pm to 9.00pm.
Also attached is ‘Project ECHO – Enhanced Security Measures’
which should be reviewed, ahead of the next Echo Session.
An agenda will be issued shortly.
Please share this with your pharmacist(s).
Yours sincerely
SENT
FOR AND BEHALF OF GERARD GREENE | Chief Executive
Download
Dear Contractor
Update to Serious Shortage Protocols: Fluoxetine 40mg Capsules
The
Department of Health NI has issued correspondence (attached) regarding the
current Serious Shortage Protocol (SSP) for fluoxetine 40mg capsules.
The
Department advises that fluoxetine 40mg capsules are now back in stock at local
wholesalers and, therefore, the SSP that is currently in force will end on
Friday 16 October 2020 and will not be renewed.
Action
Contractors are advised to: Bring the content of the letter to the attention of their dispensing teams.
Further information on SSPs is
available on the BSO website which can be accessed via this link:
CPNI colleagues will continue to support
contractors on these matters.
Kind regards
Mike
Sent
on behalf of Prof Mike Mawhinney | Head of Regulatory Affairs
Download
WhatsApp Business Terms of Service can be found here and privacy policy hereUCA-NI Privacy Policy We take your privacy seriously and do not share or sell any personal details with third parties for commercial purposes. If you have any questions, please contact the CPNI office. You can withdraw your consent to be contacted at any time by calling 028 9069 0444 or by emailing info@communitypharmacyni.co.uk. CPNI Data Protection Policy and Data Retention policy can be found Click Here
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
